Blood-recirculating devices such as blood pumps, hemodializers and membrane oxygenators are commonly applied to treat and/or bridge patients suffering from organ failure of various etiologies. It has not yet been achieved to reduce the thrombogenicity of these devices to a satisfactory degree: patients implanted with blood-recirculating implants usually receive an augmenting drug treatment to inhibit physiologically relevant coagulative cascades. Hence, the effective reduction of the thrombogenicity of blood-recirculating devices still is a major cornerstone of their development. The gold standard method to assess the thrombotic potential currently is the testing of the device in cumbersome in-vivo experiments, sacrificing animals.
In TIBET, an alternative in-vitro approach will be developed and tested in order to facilitate research and development, regulatory processes, and to better understand the process of thrombosis.
This will be realized by using porcine blood and by scaling of the time frame within which the blood forms clots down to few hours. Using various analytic tools, sensors, and imaging modalities, thrombosis can be determined qualitatively, quantitatively and/or visualized.
TIBET is a cooperative research project with Maquet Cardioplulmonary GmbH / GETINGE AB.